Direct thrombin inhibitors (Q56003309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

review article

1 reference

title

Direct thrombin inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1

Jeffrey I Weitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

author name string

Mark Crowther

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

publication date

1 May 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

page(s)

V275-84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

Molecular and cellular biology of blood coagulation

13 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

1 reference

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

A player of many parts: the spotlight falls on thrombin's structure.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Structure of the hirugen and hirulog 1 complexes of alpha-thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Hirulog-1 and -B2 thrombin specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Inhibitor binding to thrombin: x-ray crystallographic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Challenges in the conduct and interpretation of phase II (pilot) randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3,1-benzoxazin-4-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900093-2

7 January 2021

10.1016/S0049-3848(02)00093-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12356489%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference